Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines.
It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program.
Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies.
Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011.
Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 25, 24 | 1.57 Decreased by -43.32% | 1.38 Increased by +13.55% |
| Sep 12, 24 | 0.93 Decreased by -2.11% | 0.86 Increased by +8.14% |
| Apr 25, 24 | 0.97 Decreased by -16.38% | 0.94 Increased by +3.19% |
| Feb 1, 24 | 0.89 Increased by +2.30% | 1.50 Decreased by -40.67% |
| Oct 27, 23 | 2.77 Increased by +92.36% | 2.27 Increased by +22.03% |
| Jul 28, 23 | 0.95 Increased by +3.26% | 1.55 Decreased by -38.71% |
| Apr 27, 23 | 1.16 Increased by +6.42% | 1.88 Decreased by -38.30% |
| Feb 3, 23 | 0.87 Increased by +10.13% | 0.90 Decreased by -3.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 14.16 B Increased by +11.49% | 2.81 B Increased by +11.49% | Increased by +19.88% Decreased by -0.00% |
| Jun 30, 24 | 11.38 B Increased by +6.53% | 1.11 B Decreased by -22.44% | Increased by +9.78% Decreased by -27.20% |
| Mar 31, 24 | 11.12 B Increased by +2.35% | 1.13 B Decreased by -43.21% | Increased by +10.19% Decreased by -44.51% |
| Dec 31, 23 | 22.88 B Increased by +99.75% | -555.00 M Decreased by -117.84% | Decreased by -2.43% Decreased by -108.93% |
| Sep 30, 23 | 12.70 B Decreased by -3.35% | 2.52 B Increased by +21.63% | Increased by +19.89% Increased by +25.84% |
| Jun 30, 23 | 10.68 B Decreased by -0.56% | 1.44 B Increased by +22.13% | Increased by +13.43% Increased by +22.81% |
| Mar 31, 23 | 10.86 B Increased by +8.06% | 2.00 B Decreased by -0.70% | Increased by +18.37% Decreased by -8.10% |
| Dec 31, 22 | 11.46 B Increased by +10.00% | 3.11 B Increased by +175.31% | Increased by +27.16% Increased by +150.29% |